FeRx is a product-oriented, targeted drug delivery company dedicated to the development and commercialization of its proprietary MTC technology to improve patient care, reduce toxicity and increase efficacy of known drugs. FeRx is completed a Phase I/II clinical trial in the U.S. of its lead compound, MTC-Doxorubicin (MTC-DOX), in patients with primary liver cancer, began a Phase II study in China during 2001, and initiated a Phase I/II study of MTC-DOX in patients with metastatic liver cancer. action.
